Fit Over 40 Join the community

Menopause insomnia: a decision tree for hot flashes, CBT-I, hormone therapy and new drugs

Hot flashes get most of the blame for bad sleep in menopause. The measurements say they are only part of the story. This guide sorts the evidence on hot flashes, insomnia, hormone therapy, the newest nonhormonal drugs and sleep apnea into one decision tree, so you can match the treatment to the way you actually wake up.

Researched and drafted by the Fit Over 40 editorial team. Last updated November 12, 2026. 11 minute read. How we research
Woman meditating in silhouette at sunset

The short version

  • Hot flashes wake most women who have them: skin-sensor and sleep-lab studies link 69% to 78% of hot flashes to an awakening. But in 2026 interviews about SWAN data, a leading researcher said only about a third of the time women spend awake at night is tied to a hot flash.
  • In the MsFLASH trial of 106 women with hot flashes and insomnia, six phone sessions of CBT-I cut insomnia scores by 9.9 points versus 4.7 for menopause education. At 24 weeks, 84% of the CBT-I group had no insomnia versus 43%.
  • Hormone therapy improves sleep mainly in women who have hot flashes. A meta-analysis found no difference in women without them, and a second one found no effect on lab-measured sleep.
  • Elinzanetant (Lynkuet, approved in the US in October 2025) and fezolinetant (Veozah) both improved patient-reported sleep in hot flash trials. A conference analysis estimated that about 54% of elinzanetant's sleep effect did not run through fewer night hot flashes. There is no head-to-head trial.
  • Sleep apnea becomes more common after menopause. In the Wisconsin Sleep Cohort, postmenopausal women were 2.6 times as likely as premenopausal women to have sleep apnea and 3.5 times as likely to have the moderate-to-severe form.
  • CBT-I comes first for chronic insomnia. The American College of Physicians recommends sleep medicines only as a shared decision after CBT-I alone has not worked.

Hot flashes wake you up, but they are only part of the story

Sleep problems are reported by 40% to 60% of women during the menopause transition.1 In the Study of Women's Health Across the Nation (SWAN), the odds of trouble falling asleep and staying asleep rose as women moved through the transition, and women with more frequent hot flashes had higher odds of every type of sleep difficulty.2 That is why night sweats usually take the blame. Studies that record hot flashes and sleep at the same time give a more precise picture.

StudyMethodWhat it found
de Zambotti, 20143Perimenopausal women in a sleep lab, 63 nights, skin sensor for hot flashesAbout 3.5 hot flashes per night. 69% were associated with an awakening
Thurston, 20191168 midlife women at home, wrist actigraphy plus skin sensorWake episodes coincided with 78% of hot flashes. The odds of waking were about five times higher in the five minutes after a hot flash than in the ten minutes before, whether or not the woman reported the hot flash
Maki, 2026 interviews4,5Polysomnography and SWAN data, discussed around a 2026 sleep meetingWomen woke after about 75% of hot flashes, yet only about a third of their total time awake at night was linked to a hot flash

Source: the studies cited in each row. The 2026 figures come from interview coverage of conference work, not from a published paper.

Two things follow. First, a hot flash usually does wake you, and you may not remember it. Second, most of the time you spend awake at night is not caused by a hot flash. A treatment that cools the night cannot fix the rest, and a sleep treatment cannot stop the heat. In an analysis of 2,066 SWAN women presented at SLEEP 2026, sleep disturbance was tied to worse health-related quality of life than hot flashes alone, and having both was worst.5

Need more than general advice? Our community offers professional, personalized nutrition and exercise plans. Join the Fit Over 40 community

The decision tree: match the treatment to how you wake up

Find the row that sounds like your nights. Each treatment listed has randomized-trial or guideline support, and the sections below give the numbers. For habits and bedroom basics, see our guide to menopause sleep problems.

Your nightsLikely driverStart hereAdd if it is not enough
You wake hot or drenched and fall back asleep within minutesNight hot flashesTreat the hot flashes: hormone therapy for suitable candidates, or a nonhormonal drug6,7CBT-I, if you begin lying awake after the heat passes
You lie awake for a long time before sleep or after waking, even on cool nightsChronic insomniaCBT-I8,9A hot flash treatment, if night sweats also wake you
Heat wakes you, then you cannot get back to sleepNight hot flashes plus insomniaCBT-I and a hot flash treatment. Fezolinetant and elinzanetant both have measured sleep outcomes10,11Re-score your sleep after about 8 weeks
Snoring, breathing pauses someone has noticed, unrefreshing sleep or daytime sleepinessSleep apnea, whose risk rises after menopause12A sleep studyCBT-I and hot flash treatment still apply to whatever remains
Nothing above fits, or treatment has not helpedAnother primary sleep disorder, such as restless legs13A sleep medicine evaluationSleep medicines, as a shared decision after CBT-I8

Not sure which row you are in? Two weeks of a sleep diary will show it. Note when you got into bed, how long it took to fall asleep, how many times you woke, how long you stayed awake and whether you felt hot. Weekly sleep diaries were part of the CBT-I protocol in the main menopause trial.9

CBT-I: the best-supported treatment for lying awake

Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment for chronic insomnia in adults, according to both the American College of Physicians and the American Academy of Sleep Medicine.8,14 It is a bundle: sleep restriction, stimulus control, sleep hygiene education, cognitive restructuring and behavioral homework.9

The key menopause trial is MsFLASH, run in western Washington. It randomized 106 women aged 40 to 65 with moderate insomnia and at least two hot flashes a day to six telephone sessions over eight weeks of either CBT-I or menopause education.9

OutcomeCBT-IMenopause education
Drop in Insomnia Severity Index at 8 weeks9.9 points4.7 points
Drop in Pittsburgh Sleep Quality Index at 8 weeks4.0 points1.4 points
Insomnia score in the no-insomnia range at 8 weeks70% (33 of 47)24% (10 of 41)
Insomnia score in the no-insomnia range at 24 weeks84% (37 of 44)43% (16 of 37)
Number of hot flashes per dayNo difference between groups
Hot flash interference score, change at 8 weeks-15.7-7.1

Source: McCurry et al., JAMA Internal Medicine, 2016.9

Two points stand out. CBT-I did not reduce how many hot flashes women had, yet it reduced how much they interfered with daily life.9 And the comparison group received menopause education by phone, not nothing. The trial authors named a head-to-head comparison of CBT-I against medication as the logical next step.15

How long the gains last is less settled. Randomized trials in the general population have found stable improvements out to 24 months, while a meta-analysis found that gains in treated groups appeared to decline over time.16 In a 2026 pilot of 43 women with insomnia and night hot flashes, a CBT program adapted for menopause improved insomnia severity, hot flash interference, sleep confidence and depressive symptoms, but the benefits declined over three months of follow-up.17,18

In the United States, the free Insomnia Coach app from the Department of Veterans Affairs' National Center for PTSD follows a five-week training plan with a sleep diary and personal feedback on your sleep schedule.19 Maki pointed women to the VA's CBT-I platform in her 2026 interview.4 Two prescription digital CBT-I programs are FDA-cleared: Somryst, and SleepioRx, cleared in August 2024 as a 90-day program used alongside usual care.20,21

What treating the hot flashes does for sleep

Hormone therapy and sleep

Hormone therapy is the first-line treatment for hot flashes in healthy women at or around the time of menopause, according to the Menopause Society.6 Its effect on sleep depends on whether you have hot flashes. A meta-analysis of seven trials and 15,468 women found better sleep quality in women who had hot flashes at baseline (standardized mean difference -0.54) and no difference in women who did not. The trials carried a moderate to high risk of bias.22

A 2022 meta-analysis of 15 studies found a small benefit on self-reported sleep (-0.13) and none on polysomnography. Estrogen combined with a progestogen helped, estrogen alone did not, and transdermal regimens (-0.35) outperformed oral ones (-0.10).23 Maki's summary is that hormone therapy improves sleep mainly in women who also have hot flashes, and that its benefit independent of hot flashes is less clear.4

Nonhormonal drugs the Menopause Society recommends

The Menopause Society's 2023 statement gave its highest evidence rating (Level I) to CBT, clinical hypnosis, SSRIs and SNRIs, gabapentin and fezolinetant for hot flashes, and Levels I to II to oxybutynin.6 It did not recommend supplements, herbal remedies, cooling techniques, avoiding triggers, exercise, yoga, mindfulness-based interventions or relaxation as hot flash treatments, and it advised against pregabalin because of adverse events and controlled-substance restrictions.6,24 The statement was published before elinzanetant was approved in the US, so it does not rate that drug.

Fezolinetant (Veozah) versus elinzanetant (Lynkuet): what the sleep data show

Fezolinetant (Veozah)Elinzanetant (Lynkuet)
TargetNK3 receptor25NK1 and NK3 receptors7
US approvalMay 202325October 24, 20257
Patient-reported sleep disturbance at week 12 (PROMIS T-score difference versus placebo)-1.5 for the 45 mg arm. -0.6 for the 30 mg arm, not statistically significant10-5.6 and -4.3 in OASIS-1 and OASIS-2.26 -4.92 pooled across four trials, 1,345 women11
Objective sleep measuresReal-world actigraphy, no control group, 12 weeks: 9.5 fewer minutes awake after sleep onset, 2.6 fewer awakenings, sleep efficiency up about 2 percentage points27NIRVANA, polysomnography versus placebo, 12 weeks: numerically larger drop in wake time, biggest at week 428
Safety factsBoxed warning for rare but serious liver injury. Liver blood tests at baseline, monthly for two months, then at months 3, 6 and 925,29Most common adverse events: headache, fatigue, somnolence. Treatment-related events 30.4% versus 14.6% on placebo in OASIS-330. No liver toxicity reported in OASIS-1 and OASIS-231

We found no head-to-head trial, and the programs enrolled different women, so these figures are not a ranking. Elinzanetant was developed and tested by Bayer.7

The most interesting elinzanetant finding concerns mechanism. A pooled post hoc mediation analysis of 1,345 women across OASIS-1, -2 and -3 and the NIRVANA trial, presented at SLEEP 2026, estimated that 54% of the sleep benefit (95% CI 46% to 63%) did not run through fewer night hot flashes.11 NIRVANA itself was a 12-week exploratory phase 2 trial in 110 women with frequent hot flashes and polysomnography-confirmed wake time of at least 30 minutes after sleep onset. Elinzanetant produced a numerically greater reduction in wake time than placebo, most pronounced at week 4 and smaller by week 12.28 In pooled safety analyses, most first-time adverse events were mild or moderate, appeared within two weeks and resolved over time.32

When it is not insomnia: sleep apnea after menopause

In the Wisconsin Sleep Cohort, 539 women aged 30 to 60 were studied overnight. After adjusting for age, body size and lifestyle, postmenopausal women were 2.6 times as likely as premenopausal women to have an apnea-hypopnea index of 5 or more and 3.5 times as likely to have an index of 15 or more.12 In the longer-running Sleep in Midlife Women Study, 219 women were followed through the transition, and progression through menopause was linked to greater sleep-disordered breathing severity, independent of aging and body habitus.33

Hormone use was linked to less sleep apnea in observational data. In the Sleep Heart Health Study, the adjusted odds ratio for an apnea-hypopnea index above 15 was 0.36 among hormone users aged 50 to 59.12 Observational data cannot separate the drug's effect from differences between women who choose it and women who do not.

Apnea also hides inside insomnia complaints. Commentators note that many women with menopause-related sleep complaints have an underlying primary sleep disorder such as sleep apnea or restless legs syndrome.13 That is why the decision tree has a row for it.

Where sleep medicines fit

The American College of Physicians recommends CBT-I first for chronic insomnia. If CBT-I alone is unsuccessful, it recommends a shared decision about adding a drug, a weak recommendation based on low-quality evidence. Its president said medicines should ideally be used for no longer than four to five weeks while the skills from CBT-I take over, and that treatable causes such as depression, pain, sleep apnea and restless legs syndrome should be considered before continuing a drug.8 The Menopause Society's 2023 statement did not recommend suvorexant, a sleep medicine, for hot flashes.24

What we still do not know

  • Whether hormone therapy improves sleep in women who do not have hot flashes. The meta-analysis found no difference, and researchers call the independent benefit unclear.22,4
  • Whether CBT-I plus a hot flash drug beats either one alone. We did not find a randomized trial of the combination.
  • How long menopause-specific CBT-I gains last. The 2026 pilot enrolled 43 women and its benefits faded within three months.17,18
  • Whether elinzanetant's effect on objective sleep holds up in larger trials. NIRVANA was exploratory, and its wake-time difference was numerical.28
  • How CBT-I compares head to head with medication in menopausal women.15

A practical order of operations

  1. Keep a two-week sleep diary and place yourself in a row of the decision tree.
  2. If you lie awake, start a full CBT-I program. The MsFLASH program ran six phone sessions over eight weeks, and the VA's Insomnia Coach app is built around five weeks.9,19
  3. If heat wakes you, ask about hormone therapy or a nonhormonal drug, and ask which sleep outcomes it has been tested on.
  4. Re-score your sleep at about eight weeks, the point where MsFLASH measured its main result.9
  5. If sleep is still poor, or you snore or feel unrefreshed, ask for a sleep study.

Questions to take to your clinician

  • Do my nights look like insomnia, night hot flashes or both?
  • Am I a candidate for hormone therapy, and would a nonhormonal drug fit me better?
  • Is there a CBT-I program near me, by phone or digital, that I can start now?
  • Should I be screened for sleep apnea?

Related guides:

Common questions

Why can't I sleep in menopause?

Usually more than one thing is at work. In SWAN, the odds of trouble falling asleep and staying asleep rose through the transition, and hot flashes raised the odds of every type of sleep difficulty.2 Women wake after roughly three in four hot flashes, yet hot flashes account for only about a third of the time women spend awake at night.5,4 Chronic insomnia and sleep apnea fill much of the rest, and sleep apnea becomes more common after menopause.12

Do hot flashes cause menopause insomnia?

Partly. Sleep monitoring links 69% to 78% of hot flashes to an awakening.3,1 But in the MsFLASH trial, CBT-I improved insomnia without reducing the number of hot flashes, which shows that the sleep problem can be treated separately from the heat.9

Does hormone therapy help menopause insomnia?

It helps mainly when hot flashes are part of the problem. A meta-analysis found better sleep quality in women with hot flashes at baseline (standardized mean difference -0.54) and no difference in women without them.22 A 2022 meta-analysis found a small benefit on self-reported sleep, none on polysomnography, and larger effects for transdermal than oral regimens.23

Does CBT-I work for insomnia caused by menopause?

In the MsFLASH trial of 106 women with insomnia and hot flashes, telephone CBT-I lowered insomnia scores by 9.9 points versus 4.7 for menopause education. At 24 weeks, 84% of the CBT-I group had scores in the no-insomnia range versus 43%.9 The American College of Physicians and the American Academy of Sleep Medicine both recommend CBT-I as first-line treatment for chronic insomnia.8,14

Do Lynkuet (elinzanetant) and Veozah (fezolinetant) help sleep?

Both improved patient-reported sleep disturbance in trials of women with hot flashes. Elinzanetant's pooled score difference was -4.92 across four trials, and fezolinetant's was -1.5 for the 45 mg arm in two pooled trials.11,10 No head-to-head trial exists. Fezolinetant carries a boxed warning for rare but serious liver injury, with scheduled liver blood tests.25,29

Can menopause cause sleep apnea?

It is associated with it. In the Wisconsin Sleep Cohort, postmenopausal women were 2.6 times as likely as premenopausal women to have an apnea-hypopnea index of 5 or more and 3.5 times as likely to have an index of 15 or more, after adjustment for age and body size.12 A second cohort found the link independent of aging and body habitus.33

How long does menopause insomnia last?

There is no single timeline. In a SWAN analysis of 1,285 naturally menopausal women, waking several times a night followed four trajectories: low (38%), moderate (28%), increasing (15%) and high (18%) prevalence. Awakenings were generally stable from before to after the final period.34 Early-morning waking was the one pattern whose odds fell from late perimenopause to postmenopause.2

References

  1. Thurston RC, Chang Y, Buysse DJ, Hall MH, Matthews KA. Hot flashes and awakenings among midlife women. Sleep. 2019;42(9):zsz131. https://pmc.ncbi.nlm.nih.gov/articles/PMC7368339
  2. Kravitz HM, Zhao X, Bromberger JT, et al. Sleep disturbance during the menopausal transition in a multi-ethnic community sample of women. Sleep. 2008;31(7):979-990. https://pmc.ncbi.nlm.nih.gov/articles/PMC2491500
  3. de Zambotti M, Colrain IM, Javitz HS, Baker FC. Magnitude of the impact of hot flashes on sleep in perimenopausal women. Fertil Steril. 2014;102(6):1708-1715. https://pubmed.ncbi.nlm.nih.gov/25256933/
  4. Contemporary OB/GYN. Pauline Maki, PhD, on why CBT for insomnia is underused in menopause care despite strong evidence. June 29, 2026. https://www.contemporaryobgyn.net/view/pauline-maki-phd-on-why-cbt-for-insomnia-is-underused-in-menopause-care-despite-strong-evidence
  5. Contemporary OB/GYN. SWAN analysis: sleep, not VMS alone, drives quality-of-life decline in menopause (Maki P et al., SLEEP 2026 abstract). June 23, 2026. https://www.contemporaryobgyn.net/view/swan-analysis-sleep-not-vms-alone-drives-quality-of-life-decline-in-menopause
  6. Shufelt CL, et al. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590. https://doi.org/10.1097/GME.0000000000002200
  7. Contemporary OB/GYN. FDA approves elinzanetant (Lynkuet) for vasomotor menopausal symptoms. October 24, 2025. https://www.contemporaryobgyn.net/view/fda-approves-elinzanetant-lynkuet-for-vasomotor-menopausal-symptoms
  8. Sleep Review. ACP recommends cognitive behavioral therapy as initial treatment for chronic insomnia (American College of Physicians guideline, Ann Intern Med, 2016). https://sleepreviewmag.com/uncategorized/acp-recommends-cognitive-behavioral-therapy-initial-treatment-chronic-insomnia/
  9. McCurry SM, Guthrie KA, Morin CM, et al. Telephone-based cognitive behavioral therapy for insomnia in perimenopausal and postmenopausal women with vasomotor symptoms: a MsFLASH randomized clinical trial. JAMA Intern Med. 2016;176(7):913-920. https://pmc.ncbi.nlm.nih.gov/articles/PMC4935624
  10. Shapiro M, Cano A, Nappi RE, et al. Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopause. Maturitas. 2024;186:107999. https://doi.org/10.1016/j.maturitas.2024.107999
  11. Patient Care Online. Elinzanetant improves sleep independent of hot flash reduction in menopause (Maki P et al., post hoc mediation analysis, SLEEP 2026). https://www.patientcareonline.com/view/elinzanetant-improves-sleep-independent-of-hot-flash-reduction-in-menopause
  12. Obstructive sleep apnea in women: population studies on prevalence and incidence (Table 5, summarizing Young et al., Wisconsin Sleep Cohort, Am J Respir Crit Care Med 2003, and Shahar et al., Sleep Heart Health Study). PMC10359192. https://pmc.ncbi.nlm.nih.gov/articles/PMC10359192/table/T5
  13. Nonacs R. In brief: telephone-based CBT for menopause-related insomnia. MGH Center for Women's Mental Health. https://womensmentalhealth.org/?p=10647
  14. American Academy of Sleep Medicine. Digital cognitive behavioral therapy for insomnia. https://aasm.org/digital-cognitive-behavioral-therapy-for-insomnia/
  15. MedicalResearch.com. Telephone delivered cognitive behavioral therapy improved insomnia and hot flashes in menopausal women (interview with Susan McCurry, PhD). 2016. https://medicalresearch.com/?p=24608
  16. Muench A, Vargas I, Grandner MA, et al. We know CBT-I works, now what? Fac Rev. 2022;11:4. https://pmc.ncbi.nlm.nih.gov/articles/PMC8808745
  17. Arentson-Lantz E, et al. Cognitive behavioral therapy for menopausal insomnia in perimenopausal and postmenopausal women with insomnia and nocturnal hot flashes: a randomized-controlled pilot trial. Menopause. 2026 (online May 5). https://menopause.org/wp-content/uploads/press-release/MENO-D-25-00387.pdf
  18. Nonacs R. CBT for menopause: improving sleep and hot flashes without medication. MGH Center for Women's Mental Health. https://womensmentalhealth.org/posts/nk3r-antagonists-menopause-vasomotor-symptoms-fezolinetant-elinzanetant/
  19. US Department of Veterans Affairs, National Center for PTSD. Insomnia Coach (mobile app listing). https://apps.apple.com/us/app/insomnia-coach/id1341944736
  20. American Academy of Sleep Medicine. Digital CBT-I platforms and characteristics. https://aasm.org/digital-cognitive-behavioral-therapy-for-insomnia-platforms-and-characteristics/
  21. American Academy of Sleep Medicine. FDA clears SleepioRx for chronic insomnia (Big Health clearance announced August 8, 2024). https://aasm.org/fda-clears-sleepiorx-for-chronic-insomnia/
  22. Cintron D, Lipford M, Larrea-Mantilla L, et al. Efficacy of menopausal hormone therapy on sleep quality: systematic review and meta-analysis. Endocrine. 2017;55(3):702-711. https://pubmed.ncbi.nlm.nih.gov/27515805/
  23. Pan Z, Wen S, Qiao X, et al. Different regimens of menopausal hormone therapy for improving sleep quality: a systematic review and meta-analysis. Menopause. 2022;29(5):627-635. https://pmc.ncbi.nlm.nih.gov/articles/PMC9060837
  24. Guideline Central. Nonhormonal management of menopause-associated vasomotor symptoms (summary of the 2023 NAMS position statement). https://guidelinecentral.com/guideline/9842
  25. US Food and Drug Administration. FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause. Updated December 16, 2024. https://www.fda.gov/drugs/drug-safety-communications/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due
  26. Pinkerton JV, Simon JA, Joffe H, et al. Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials. JAMA. 2024;332(16):1343-1354. https://doi.org/10.1001/jama.2024.14618
  27. Contemporary OB/GYN. Real-world data link fezolinetant to fewer nighttime awakenings (OPTION-VMS, presented at the IMS 20th World Congress, 2026). https://www.contemporaryobgyn.net/view/real-world-data-link-fezolinetant-to-fewer-nighttime-awakenings
  28. Contemporary OB/GYN. NIRVANA: elinzanetant cuts objective wakefulness in menopausal women (Soares CN et al., SLEEP 2026 abstract). June 17, 2026. https://www.contemporaryobgyn.net/view/nirvana-elinzanetant-cuts-objective-wakefulness-in-menopausal-women
  29. Healio. FDA adds boxed warning to hot flash drug Veozah due to liver injury risk. December 18, 2024. https://cm.healio.com/news/womens-health-ob-gyn/20241218/fda-adds-boxed-warning-to-hot-flash-drug-veozah-due-to-liver-injury-risk
  30. Pharmacy Times. Elinzanetant reduces frequency, severity of VMS in differing female populations (OASIS-1 to -4). October 21, 2025. https://www.pharmacytimes.com/view/elinzanetant-reduces-frequency-severity-of-vms-in-differing-female-populations
  31. Healio. OASIS: nonhormonal elinzanetant improves hot flashes, menopause-related quality of life. August 22, 2024. https://www.healio.com/news/womens-health-ob-gyn/20240822/oasis-nonhormonal-elinzanetant-improves-hot-flashes-menopauserelated-quality-of-life
  32. Contemporary OB/GYN. JoAnn V. Pinkerton, MD, on elinzanetant across menopause subpopulations at The Menopause Society 2026 meeting (pooled safety analysis). October 21, 2026. https://www.contemporaryobgyn.net/view/joann-v-pinkerton-md-mscp-on-elinzanetant-across-menopause-subpopulations-at-tms-2026
  33. Sleep-disordered breathing and the menopausal transition in the Sleep in Midlife Women Study (219 women, Wisconsin Sleep Cohort). PMC5266663. https://pmc.ncbi.nlm.nih.gov/articles/PMC5266663
  34. Kravitz HM, Janssen I, Bromberger JT, et al. Sleep trajectories before and after the final menstrual period in the Study of Women's Health Across the Nation (SWAN). Curr Sleep Med Rep. 2017;3(3):235-250. https://research.bidmc.org/rhyme/publications/sleep-trajectories-and-after-final-menstrual-period-study-womens-health-across-nation
About this article

Every health claim above links to its source. It is general information and cannot take your personal history into account, so use it to prepare for a conversation with your own clinician.

Spotted an error? Tell us and we will check it.

Keep reading